Compare VRCA & KEQU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | KEQU |
|---|---|---|
| Founded | 2013 | 1906 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.3M | 110.9M |
| IPO Year | 2018 | 1995 |
| Metric | VRCA | KEQU |
|---|---|---|
| Price | $6.15 | $41.19 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $17.00 | N/A |
| AVG Volume (30 Days) | ★ 83.8K | 1.2K |
| Earning Date | 05-11-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.09 |
| Revenue | $35,577,000.00 | ★ $138,558,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $94.44 | N/A |
| P/E Ratio | ★ N/A | $19.63 |
| Revenue Growth | ★ 370.22 | 7.72 |
| 52 Week Low | $0.49 | $33.70 |
| 52 Week High | $9.82 | $60.89 |
| Indicator | VRCA | KEQU |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 69.87 |
| Support Level | $5.13 | $37.04 |
| Resistance Level | $6.40 | $41.26 |
| Average True Range (ATR) | 0.73 | 1.18 |
| MACD | -0.20 | 0.40 |
| Stochastic Oscillator | 21.52 | 99.83 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.